Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ipilimumab, Nivolumab and Brentuximab Vedotin in Relapsed/Refractory Hodgkin Lymphoma
NCT01896999Phase 2Active, not recruiting
- Sponsor
- National Cancer Institute
- Start
- Mar 2014
- Primary completion
- Jun 2027
- Countries
- 1
01
Overview
A Phase 2 trial of ipilimumab, nivolumab, brentuximab vedotin in Hodgkin lymphoma (HL), sponsored by National Cancer Institute. Started Mar 2014; status: active, not recruiting.
02
Drugs
03
Conditions
Hodgkin lymphoma (HL)
Beyond the preview
Go deeper on NCT01896999.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01896999.